title: Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
abstract: We report a case of a 77-year-old Caucasian woman, treated with ocriplasmin injection for vitreomacular traction (VMT) and full-thickness macular hole (FTMH), who had a persistence outer retinal defect on her 28-day review, without VMT resolution, then presented 3 months later with complete macular hole closure, with persistence of vitreomacular adhesion. This case raises the question on the validity of the 28-day fixed date to assess final outcome of ocriplasmin injection for FTMH associated with VMT, and sheds new lights on the behaviour of the posterior hyaloid in cases of vitreolysis by a chemical agent such as ocriplasmin.
authors.affiliation: Eye Unit, East Surrey Hospital, Redhill, Surrey, UK.
authors.forename: Sleiman
authors.initials: S
authors.lastname: Abou Ltaif
authors.affiliation: Eye Unit, East Surrey Hospital, Redhill, Surrey, UK.
authors.forename: Luke
authors.initials: L
authors.lastname: Herbert
mesh_terms: D000368:Aged; D005128:Eye Diseases / Q000188:drug therapy; D005260:Female; D005341:Fibrinolysin / Q000494:pharmacology / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D012160:Retina / Q000473:pathology*; D012167:Retinal Perforations / Q000188:drug therapy*; D000267:Tissue Adhesions / Q000188:drug therapy*; D014143:Traction; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin